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As genomicmedicine gains clinical applicability across a spectrumof diseases, insufficient application in low-income settings stands
to increase health disparity. Breast cancer screening, diagnosis, and treatment have benefited greatly from genomic medicine in
high-income settings. As breast cancer is a leading cause of both cancer incidence and mortality in Africa, attention and resources
must be applied to research and clinical initiatives to integrate genomic medicine into breast cancer care. In terms of research,
there is a paucity of investigations into genetic determinants of breast cancer specific to African populations, despite consensus
in the literature that predisposition and susceptibility genes vary between populations. Therefore, we need targeted strengthening
of existing research efforts and support of new initiatives. Results will improve clinical care through screening and diagnosis with
genetic testing specific to breast cancer in African populations. Clinically, genomic medicine can provide information capable
of improving resource allocation to the population which most stands to benefit from increased screening or tailored treatment
modalities. In situations where mammography or chemotherapy options are limited, this information will allow for the greatest
impact. Implementation of genomic medicine will face numerous systemic barriers but is essential to improve breast cancer
outcomes and survival.
1. Introduction
The clinical spectrum of breast cancer management, from
screening to diagnosis to treatment, benefits widely from
applications of genomic medicine in high-income countries
(HICs).With genomicmedicine rapidly emerging as ameans
for personalized and improved medical care, attention must
be paid to research and integration in low-income settings.
Otherwise, disparate implementation of genomic technol-
ogy will continue to heighten existing health disparities
[1, 2].
Women who present to their gynecologists, surgeons,
and other healthcare providers in HICs may undergo genetic
testing to evaluate the presence of specific mutations linked
to increased breast cancer risk. These results not only guide
screening decisions, but also have the potential to influence
prophylacticmedical and surgical treatment options. Further,
upon diagnosis of breast cancer, immunohistochemistry
studies can identify geneticmarkers to characterize the tumor
and enable targeted treatment. Patients may elect to use
broader genetic panels, such as Oncotype DX, which help
determine risk of recurrence to further tailor treatment
recommendations [3–5].
The Global Burden of Cancer 2013 asserted that breast
cancer is a leading cause of cancer death in Africa and has
the highest incidence of all cancers [6]. Although breast
cancer is themost common cancer inwomenworldwide, case
fatality rates are highest in low- andmiddle-income countries
(LMICs) [7, 8]. We argue that research and implementation
efforts must be undertaken to similarly integrate genomic
medicine into breast cancer care in Africa and that doing so
has tremendous potential to improve outcomes and survival.
The need for continent-wide focus on improving breast
cancer outcomes is clear.
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2. A Research Agenda for Africa
There is a paucity of well-powered research investigating
the possibility of genetic predisposition to breast cancer in
Africa [9, 10].This lack of research impairs our ability to fully
understand disease presentation and progression. Studies
suggest that hereditary mutations are responsible for up to
5% of patients presenting with breast cancer [10]. While
novel BRCA mutations have been discovered in Afrikaner
populations [11], we must work on creating and increasing
the existence of broad breast cancer genetic registries specific
to and with recognition of the variability in the African
population. A 2012 systematic literature review found that
there was less than one study per year in the African popu-
lation since the discovery of the BRCA gene; this is far from
sufficient. Further, studies that have discovered new germ line
mutations have been underpowered to make generalizations
about the population [10]. In the African population where
tumor characteristics appear to be different, wemust uncover
new genetic patterns and utilize our findings to diagnose
cases earlier and improve care.
Disparities in racial representation in research are not
limited simply to breast cancer; despite knowledge that
genetic variants have different effects in different ethnic
groups, 96% of subjects included in genome-wide association
studies (GWAS) are of European descent [12]. Additionally,
African populations demonstrate more genetic diversity than
on other continents and require differentiation of sub-
populations in investigating genetic determinants of health
[13].
Initiatives such as the Human Heredity and Health
(H3) Network aim to facilitate research about genomics and
environmental determinants of common diseases to improve
the health of Africans. Among a number of ongoing projects
is the H3Africa Kidney Disease Research Network, which
studies prevalent forms of kidney disease in sub-Saharan
Africa. In addition to the collection and analysis of genetic
information, they strive to build research capacity by training
relevant personnel and developing facilities that can support
genetic analyses and storage of information in Africa [14].
While this strategywill help bridge the existing divide forH3’s
targeted diseases and ultimately have broader implications,
we maintain that a greater focus must be placed on breast
cancer at this time.
3. Genomic Medicine in Clinical Care
Expansion of genomic medicine research specific to African
populations will generate knowledge for future innovation
and ultimately enable clinical applications. An understanding
of current applications of and limitations to the integration
of genomic medicine into breast cancer screening and care
in Africa is essential to designing an effective plan for
the future. Knowledge of genetic predisposition can alter
patients’ treatment decisions before they even develop cancer;
in high-resource settings, BRCA+mutation carriersmay elect
to undergo prophylacticmastectomy or oophorectomy or opt
for nonsurgical methods of risk reduction [15, 16]. Ultimately,
this can help reduce the cost and discomfort associated with
recurrent surgeries. In South Africa, for example, where
genetic testing for BRCA mutations has been available since
2005, in order to conserve resources, women affected with
breast cancer are first tested instead of the “worried well”
[16]. In addition to integrating BRCA1/2 genetic testing, if
we can identify novel genetic mutations, we can combine this
information to assist families of patients by testing them for
the same mutations and guiding them to personalize their
screening and treatment options.
However, given the financial and resource limitations to
universally available genetic testing in low-income health
systems, a simple family history can serve as a marker for
increased breast cancer risk [17, 18]. A case-control study
in Nigeria evaluating 250 women with breast cancer and
250 age-matched controls found that family history of breast
cancer was associated with a 15-fold increase of breast cancer
[17]. There are multiple risk stratification tools that consider
parameters, including family history of disease, age, parity,
history of breastfeeding, and other demographic or social
factors that may be easily asked of patients. These tools are
used in HICs to adjust recommended frequency and type of
screening and could be implemented at low cost and resource
use in African countries.
Unfortunately, even if such scoring systems were utilized
in said settings, many hospitals and countries face severe
limitations in availability and utilization of screening and
diagnostic services. A 2013 study in Nigeria investigating
financial barriers to utilization of screening and treatment
services of breast cancer noted that few centers have func-
tional radiotherapy equipment and, where available, high
costs limit widespread utilization [19]. Additional studies
have also found direct links between poverty and low usage
of mammography screenings [20]. The Breast Health Global
Initiative guidelines recommend utilization of ultrasound in
settings with limited resources and only recommend diag-
nostic mammography in settings where there are enhanced
or maximal resources. However, they also acknowledge that
screening mammography is the only single modality demon-
strating improved breast cancer mortality in prospective
randomized trials [21]. Integration of genomic medicine into
screening plan design may help countries selectively choose
how to best allocate their limited resources and would allow
for broadening of screening services, specifically first to those
most in need. As screening services continue to expand and
are offered to the entirety of the country, countries could
eventually employ risk stratification to alter the frequency of
the services.
Breast cancer patients in Africa more commonly present
at young ages and with advanced-stage disease [7, 22–24].
As a result, breast conservation surgery is often not an
option and patients experience higher mortality rates [7].
Breast cancer mortality can most effectively be reduced
via early detection and subsequent appropriate treatment—
options that are more readily possible via integration of
genomic medicine [24]. More so, advanced breast cancer
requires more extensive utilization of resources; thus, efforts
to identify cases early may also provide the most substantial
benefit in terms of reducing cost [25]. While the mastectomy
rate is 30% in Europe [26, 27], it is greater than 85% in some
International Journal of Breast Cancer 3
regions of Africa [28]. Although lack of screening, diagnostic
capabilities, or social determinants may influence differences
in breast cancer care among the African population, one
must question whether variations in genetics influence this
distinct, aggressive presentation of breast cancer and its
outcomes [9].
One of the first applications of genomic medicine into
breast cancer care in HICs was the identification of estro-
gen receptor (ER), progesterone receptor (PR), and human
epidermal growth factor receptor 2 (HER2) tumor markers
to target treatment. Unfortunately, receptor testing is not
available or not routinely utilized in many low-resource
settings, therefore inhibiting proper clinical distribution of
endocrine therapy to those patients who will most likely
respond [22, 29, 30]. Immunohistochemistry is arguably even
more important in LMICs given the desire to avoid waste
of limited resources on patients who will not respond to
a specific treatment, for example, treating an ER negative
patient with tamoxifen. Savings associated with selective use
of hormonal therapy are greater than those costs associated
with hormone-receptor testing [23, 25].
Studies have repeatedly revealed that African populations
aremore likely to possess triple negative tumors; these tumors
are characterized by their aggressive nature and ineffective
response to hormone therapy [23, 28, 31, 32]. While we do
recommend continued testing to characterize tumors, we
must also acknowledge the common tumor characteristics
among the African population. Accordingly, we must work
to identify new tumor markers and new therapies for triple
negative tumors to optimally aid these populations.
4. Conclusion: A Call to Action
In the era of evolving medicine and advances in genomic
medicine, limited applications of genomic medicine in
LMICs further highlight the overall lack of equity in cancer
care around the world. As money and time are invested in
developing national cancer control plans and implementing
screening guidelines, so too should attention be paid to
genomic medicine and its opportunity to enhance cancer
screening, diagnosis, and treatment. We need to recognize
that genomic medicine is an emerging field in Africa and
other LMICs and not just HICs.
Strengthening Africa’s healthcare system in parallel with
integrating genomic information will ultimately allow for the
best care for patients. First, in generating and strengthening
cancer control plans, countries must clinically integrate
genomic medicine to best allocate already limited resources.
Second, genetic variance must be considered amidst the
African population and drive targeted research and screen-
ing. Implementing the above strategies will not be easy;
however, success in doing so can drastically change the care
and outcomes of future breast cancer patients.
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